Notice of Information: FNIH Cancer Steering Committee Project Concepts for Novel Biomarker Platforms in Understanding Tumor Heterogeneity
Notice Number:

Key Dates

Release Date:

July 27, 2020

Related Announcements


Issued by

National Cancer Institute (NCI)


Solicitation Announcement

Requests for Proposal information and application forms can be found here:


The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) is issuing a Request for Proposals (RFP) for novel biomarker platforms to support the mission of the BC Cancer Steering Committee (CSC) High Content Data Integration Working Group (HCDI WG). The mission of the HCDI WG is to develop and support pilot projects that use emerging technology platforms with the potential to overcome limitations of established methodologies in the application of multi-dimensional biomarkers. The working group is focused on technologies that have the potential to address recognized clinical challenges, such as for development of tailored signatures for patient stratification, alternatives to solid biopsies, and advanced imaging technologies. The working group provides project teams with development and implementation guidance to generate fundable projects that fit the intended use of a technology and potentially enable rational clinical decisions.

The HCDI WG invites investigators to submit brief project concept proposals for application of novel biomarker platforms to either of two clinical challenges. These proposals will be considered for funding under the BC precompetitive project model. The working group is currently focused on identifying precompetitive, testable technical solutions with potential for commercialization that address the characterization of tumor heterogeneity:

  • Novel tissue imaging platforms to characterize tumor heterogeneity, tissue spatial connections/spatial heterogeneity. Particularly, given tumor heterogeneity, identify what is the minimal specimen required for assessment across multiple tumor types. This may involve the use of any of multiple imaging modalities (e.g., multiplex IHC, optical microscopy, image analysis, informatics and machine learning, spatial transcriptomics, and/or single cell sequencing) to characterize tissue.
  • A blood-based or remote sensing technology that can be used to replace solid tumor biopsies and to understand cancer of unknown origin or tumor heterogeneity to enable meaningful clinical intervention opportunities. For example, computational technologies or unique, novel blood-based technologies, e.g., methylation, single-cell profiling, deep sequencing, or nucleic acid fragmentation.

The Receipt Date for this RFP is August 31, 2020, 11:59 PM ET. See:


Please direct all inquiries to:

Dana Connors
FNIH Biomarkers Consortium

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices